金城医药：金城泰尔瑞巴派特片和金城金素注射用头孢唑肟钠拟中选本次集中采购

Core Viewpoint - Jincheng Pharmaceutical announced participation in the 11th national centralized drug procurement organized by the Joint Procurement Office, with two of its products expected to be selected for procurement [1] Company Summary - Jincheng Pharmaceutical's wholly-owned subsidiary, Beijing Jincheng Tail Pharmaceutical Co., Ltd., and its controlling subsidiary, Guangdong Jincheng Jinsu Pharmaceutical Co., Ltd., are involved in the bidding process for the centralized procurement [1] - The two products involved are Jincheng Tail's Ribavirin Tablets and Jincheng Jinsu's Injectable Cefazolin Sodium [1] - The company's revenue composition for 2024 is projected to be 100% from the pharmaceutical manufacturing industry [1] - As of the announcement, Jincheng Pharmaceutical has a market capitalization of 6.6 billion yuan [1]